Investigating depression in multiple sclerosis: an Italian Delphi consensus on clinical manifestations, diagnosis and treatment

TL;DR

This study provides expert consensus on diagnosing and treating depression in multiple sclerosis patients in Italy.

Contribution

The paper presents a Delphi consensus among Italian MS experts on depression's clinical features, diagnosis, and treatment.

Findings

Depressive symptoms often precede the onset of multiple sclerosis.

Experts agreed that DSM-5 criteria should be adapted for MS-specific mood disturbances.

Antidepressants are widely used, but their efficacy in MS patients remains uncertain.

Abstract

In multiple sclerosis (MS), depression represents one of the most frequent psychiatric comorbidities, significantly impacting patients’ quality of life and disease progression. However, the diagnosis and management of depression in MS remain challenging due to overlapping symptoms and the lack of specific treatment guidelines. This Delphi study aims to achieve a shared consensus among Italian MS experts regarding the clinical manifestations, diagnosis, and treatment of depression in MS.

An online Delphi survey with 35 questions covering the epidemiology, clinical features, diagnostic criteria, and treatment of depression in MS was anonymously administered to a panel of 51 expert neurologists across Italy. The consensus was based on a two-round Delphi process.

Consensus was reached on 100% of the statements. Positive consensus was achieved on 90.6% of the statements, while 9.4% reached negative consensus. Key findings include the strong link between depression and MS, with depressive symptoms often preceding MS onset. The panel agreed that the DSM-5 diagnostic criteria should be adapted to capture the specific mood disturbances seen in MS. Regarding treatment, antidepressants were widely prescribed, but concerns about their efficacy in the MS population remain. Non-pharmacological interventions, such as cognitive behavioral therapy (CBT), were considered essential components of comprehensive care.

This Delphi study highlights the need for tailored diagnostic tools and integrated treatment approaches for managing depression in MS. Further studies are required to refine guidelines for the use of antidepressants and explore the role of disease-modifying therapies (DMTs) in treating depression in this population.

Figures